Genvoya (elvitegravir, cobicistat, emtricitabine, tenofovir alafenamide) is indicated for use as a complete regimen for the treatment of HIV 1 infection and must not be administered with other antiretroviral products. Furthermore, Genvoya contains tenofovir alafenamide and emtricitabine and should not be administered with tenofovir-DF or additional emtricitabine (both components of Truvada).
Emtricitabine/tenofovir-DF should not be administered concomitantly with other medicinal products containing emtricitabine or tenofovir alafenamide.
Truvada Summary of Product Characteristics Gilead Sciences Ltd, June 2018.
View all available interactions with
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP) by clicking